|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
DiscoveRx Corporation Release: Comprehensive PathHunter® Assay Portfolio Driving Antibody Therapeutic Discovery Programs
5/1/2012 9:13:53 AM
FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corporation, a global provider of innovative assay solutions used in assay development, drug screening and profiling, announced that its PathHunter assays are gaining widespread adoption in large molecule therapeutic discovery campaigns and especially for discovery, characterization and functional QC of antibody therapeutics. In the last 5 years, therapeutics discovery has continued to move toward large molecules and biologics for drug development, in areas previously dominated by small molecules. Now, the scientific community has access to over 400 PathHunter GPCR, Kinase and signaling bio-assays to expedite discovery of neutralizing, blocking or activating antibodies. This proven platform exhibits unparalleled specificity, reliability and sensitivity compatible with a variety of antibody samples such as phage supernatants, sera and hybridoma culture.
|
|
|
|
|
|
|
|
|
|
|